Abstract
Increasing evidence of brain-immune crosstalk raises expectations for the efficacy of novel immunotherapies in Alzheimer’s disease (AD), but the lack of methods to examine brain tissues makes it difficult to evaluate therapeutics. Here, we investigated the changes in spatial transcriptomic signatures and brain cell types using the 10x Genomics Visium platform in immune-modulated AD models after various treatments. To proceed with an analysis suitable for barcode-based spatial transcriptomics, we first organized a workflow for segmentation of neuroanatomical regions, establishment of appropriate gene combinations, and comprehensive review of altered brain cell signatures. Ultimately, we investigated spatial transcriptomic changes following administration of immunomodulators, NK cell supplements and an anti-CD4 antibody, which ameliorated behavior impairment, and designated brain cells and regions showing probable associations with behavior changes. We provided the customized analytic pipeline into an application named STquantool. Thus, we anticipate that our approach can help researchers interpret the real action of drug candidates by simultaneously investigating the dynamics of all transcripts for the development of novel AD therapeutics.
Original language | English |
---|---|
Article number | 516 |
Journal | BMC Genomics |
Volume | 25 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2024 |
Bibliographical note
Publisher Copyright:© The Author(s) 2024.
Keywords
- Brain imaging
- Cell state annotation
- Cell type decomposition
- Immunomodulatory therapy
- Major brain cells
- Rare immune cells
- Spatial transcriptomics